HYCOR Biomedical, a manufacturer and marketer of in vitro diagnostic products for the global allergy and autoimmune markets, has sold its urinalysis business to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital. HYCOR is a portfolio company of Linden Capital Partners.
